NC 2600

Drug Profile

NC 2600

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Kyushu University; Nippon Chemiphar
  • Class Analgesics
  • Mechanism of Action Purinoceptor P2X antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuropathic pain

Most Recent Events

  • 26 Sep 2016 Safety and pharmacodynamic data from preclinical trials in Neuropathic pain presented at the 16th World Congress on Pain (WCP-2016)
  • 17 Jun 2016 Phase-I clinical trials in Neuropathic pain in Japan (PO)
  • 01 Jun 2015 Preclinical trials in Neuropathic pain in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top